Our findings resolve this discrepancy by demonstrating context-dependent roles: In breast cancer, EGR3 downregulation correlates with advanced stages and immunosuppression, while its overexpression inhibits proliferation and enhances CTL activity. Here, EGR3 is linked to breast cancer.